Completed PHASE1 INTERVENTIONAL NCT00112216

Immunotherapy of Melanoma Patients

Specific Immunotherapy of Skin Melanoma Patients With Antigenic Peptides and Immunological Analysis of the Vaccine Site Sentinel Lymph Node

Sponsor: Centre Hospitalier Universitaire Vaudois

Conditions Melanoma

Interventions FluMa peptide Mage-A10 peptide Melan-A analog peptide Montanide adjuvant SB AS-2 adjuvant

Updated 6 times since 2017 Last updated: Apr 23, 2013 Started: May 31, 1999 Primary completion: Jun 30, 2007 Completion: Jun 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Melanoma, this trial is completed. The trial is conducted by Centre Hospitalier Universitaire Vaudois and has accumulated 6 data snapshots since 1999. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE1
Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

May 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre Hospitalier Universitaire Vaudois

Data source: Centre Hospitalier Universitaire Vaudois

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lausanne, Switzerland